As I said before the stock market is really a function of supply and demand. We can't control how much others want the stock but we can affect the supply as their is a finite quantity of shares available. Hold tight to your shares until you see the full valuation of this drug platform. The manipulators have controlled this stock for last 3 yrs by preying on fears/rumors - this was trading closer to $14 less than 2yrs ago before the BS about safety/clinical hold. We knew that was not true and this has been confirmed with FDA lifting the hold and subsequent dog safety studies. The shorts/funds that wanted to steal shares used these fears to drive the stock even to below $3 last summer. Now we can see how they manipulate stock to their adavntage and get your shares. As for valuation, I think at a minimum this platform should currently be valued closer to $500-$700 MM mkt cap. Once the ph3 clinical trials in CF come out - you will see the validation of the drug platform and analysts and investors look at the mkt for both CF and NTM - then it is my feeling that we will see a rapid increase in valuation $1B plus as there are other applications in pulmonary and other settings using this technology. I have also said that it will be obvious when the institutions come for your shares - like going through eye of needle when shares are not available for sale. I say that we have been screwed for years in the valuation of this company - now that we are closer to catalysts/validation lets turn the tables on the manipulators and make them pay fair value for the shares....=) Apologize in advance for the long msg.
Validation is coming- we will not have to wait long...:) think we will hear some FDA developments for NTM before Russell addition and CF data. More fun for shorts and Russell index guys as they will scramble to get shares....:)
In reality I doubt whether we'll ever see the maximum value here. Big pharma is running out of bullets with very few blockbuster drugs coming online to replace the large number of drugs moving off patent. This is why biotech indexes have moved up almost 40% in the past year. Insmed will be bought out long before all of their potential is realized but, realistically, these big companies have the resources to drive growth and new products much, much more quickly and some have likely already run the numbers.
A rational post from the past. The "bullet" with INSM is the biofilm soluable, macro(phage)phillic liposome. There are quite a few drugs that target the lung that would be better delivered by a "depot" delivery system for the lungs. As I have said, having learned from an immunopathologist Dr. FQ of Tufts, Cornell and Rockefeller, the lung has its own immune system (as does other organ systems with mucous membranes). The big application that I see is pulmonary vaccination, which is mediated through the macrophages of the lung. With all kinds of pulmonary route infections, let alone the ones that attack the lungs, this is the direct route for preventive vaccination. Two deep breaths and phase one immunity is accomplished. But let's see what WL has to say on Tuesday.
Sentiment: Strong Buy